Both, IGF2 and its receptor IGF1R constitute desirable therapeutic targets; mainly due to these evidences showing that targeting either IGF2 or its receptor IGF1R, blocks cancer progression and displays significant antitumor activity (Xing et al., 2021). The gene discussed is IGF1R; the disease is cancer.